MAVENIR
15.12.2022 08:01:32 CET | Business Wire | Press release
Mavenir today announces the completion of radio integration at the Joint European O-RAN and TIP PlugFest, part of the O-RAN Global PlugFest Fall 2022, at the i14yLab in Berlin, hosted by Deutsche Telekom, EANTC and Vodafone. Mavenir validated its massive MIMO (mMIMO) 32TRX Active Antenna Unit (AAU) for open integration with the Keysight Technologies O-RU conformance and certification testing solution.
Mavenir’s OpenBeam mMIMO 32TRX AAU, is a high-performance O-RAN based Radio Unit (O-RU) supporting 400Mhz instantaneous bandwidth and 200 Mhz occupied bandwidth to meet high capacity and RAN sharing use cases. At 16.8kg, utilizing just passive cooling technology, it is one of industry’s lightest AAU, with uncompromising performance delivering 240W output power and high bandwidth. The AAU utilizes Zero-Force Beamforming technology to maximize performance while minimizing interference.
BG Kumar, President of Mavenir’s Access Networks, Platforms and MDE, said, “Mavenir has further strengthened the Open RAN ecosystem by introducing a competitive, high performance 32TRX mMIMO AAU O-RU product. Through the successful integration and testing at the PlugFest in Berlin, Mavenir aims to accelerate the adoption of open, disaggregated and standards-based solutions.”
Mavenir demonstrated the 32TRX AAU at PlugFest using Keysight’s Open RAN Studio Open RAN Distributed Unit (O-DU) emulator, VXT PXI Vector Transceiver, MXA/MXG signal generators, and PathWave Test Automation framework.
The 32TRX mMIMO AAU is part of the OpenBeam portfolio featuring energy efficiency capabilities, delivering savings of over 80% power consumption during idle periods. It also reduces Total Cost of Ownership (TCO) by employing AI/ML based intelligent automation for fault management, beamforming, energy efficiency, load balancing and improved network performance when used as part of Mavenir’s Open vRAN Solution. Initial 32TRX mMIMO AAU products launched this year cover 3.3GHz to 3.8GHz, targeting Europe, the Americas, and South-East Asia.
In addition to the massive MIMO AAU showcased for integration at the PlugFest, the OpenBeam O-RU portfolio also includes mmWave AAUs and multi-band RRUs for improved network capacity. The OpenBeam O-RUs are available across all frequency bands and can be used for a wide range of use cases, including enterprise and public networks for urban or rural environments.
Mavenir’s participation at the PlugFest builds upon ongoing engagements and progresses current activity in the region. Earlier in the year, Mavenir expanded its European capabilities with the establishment of an Open RAN Centre of Excellence in Germany, strengthening Mavenir’s multinational organisation by delivering regional focus, driving the knowledge and innovation across the region.
About Mavenir
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers.
i14yLab
The i14y Lab is an open lab for interoperability testing of disaggregated telco systems, such as Open RAN. The lab is operated by a consortium of strong academic and industry partners led by Deutsche Telekom and supported with funding from the German Ministry of Digital and Transport (BMDV).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005908/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom